Clinical Trial Update: An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia [Phase 4]

View source ↗

Summary

A Phase 4 open-label study assessing safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in cervical dystonia; completed with posted results in 2009.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Dystonia

Drugs mentioned

• MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution (Botulinum toxin type B)

Snippet

Sponsor: Solstice Neurosciences | Conditions: Cervical Dystonia | Phase 4 | Status: COMPLETED | Results posted: 2009-09-23